# NCT05374512 (NCT05374512)

> A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05374512
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Breast Cancer
- Interventions: Dato-DXd; Paclitaxel; Nab-paclitaxel; Carboplatin; Capecitabine; Eribulin mesylate
- Enrollment: 644
- Primary outcome: Progression Free Survival (PFS)
- Primary outcome: Overall Survival (OS)

## Commentary we found

- X threads: 100
- YouTube: 61
- Podcasts: 38
- X videos: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct05374512

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05374512", "email": "<work email>"}; the inbox owner confirms by the emailed link.